Tirzepatide 120mg

A single peptide that activates both the GIP and GLP-1 receptors, the two gut hormones that respond to food, and the first dual agonist of its kind. It suppresses appetite, slows stomach emptying and improves insulin response more strongly than GLP-1 alone. It is approved for type 2 diabetes as Mounjaro and for obesity as Zepbound, produced around 21-22% weight loss at 72 weeks in the SURMOUNT trials, and is also approved for obstructive sleep apnoea in obesity. Available in vials from 5mg to 120mg.